ข่าวประชาสัมพันธ์ breast cancer+Estee Lauder
The Estee Lauder Companies in collaboration with the National Cancer Institute and Bangkok Metropolitan Administration (BMA) organized a proactive project
The Estee Lauder Companies in collaboration with the National Cancer Institute and Bangkok Metropolitan Administration (BMA) organized a proactive project under Breast Cancer Campaign providing cancer screening for more than 1,500 working-age women in Thailand between 30 31 October and during the month of November 2023. The Estee Lauder Companies furthers its mission to eradicate breast cancer from the world through its Breast Cancer Campaign conducted under a collaboration with the National
The Estee Lauder Companies joins hands with National Cancer Institute to continue the mission of eradicating breast cancer from the world
—
Under the Brea...
Entering our 30th year with The Estee Lauder Companies and our mission to eradicate breast cancer globally.
—
The Estee Lauder Companies are carrying on E...
AXA Strengthens Cancer Awareness and Prevention Efforts in Thailand
—
Cancer remains one of the most pressing health challenges in Thailand, with over 180...
Is it really acceptable? 22 women in Thailand lose their lives to breast cancer each day. Thanyarak Foundation x True invite you to reduce the risk with 'Breast must be checked'—can't wait, the sooner, the better
BDMS Wellness Clinic Joins Forces with Bangkok Cancer Hospital Wattanosothto Advocate for the "Voice of Care for Breast Cancer,"
—
BDMS Wellness Clinic Jo...
BDMS Launches Breast Cancer Screening Campaign to Promote Early Detection and Prevention
—
Bangkok Dusit Medical Services Public Company Limited (BDMS), a...
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection , securing exclusive commercialization licensing and supply of...Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor...Menarini Group Announces New Data on ORSERDU(R) (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS(R) (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition
- Data spans eleven presentations across both solid tumors and hematologic malign...
Krungsri supports Breast Foundation in screening breast cancer for disadvantaged women for 14th year
—
Mr. Poonsit Wongthawatchai (left), Krungsri Executi...
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU(R) (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metas...
Olight 2023 Breast Cancer Charity Campaign: Illuminating Hope with Breast Cancer Foundations Across the World
—
Olight, a leading mobile lighting manufact...
Thanyarak Foundation collabs with True Bangkok United, invites Thai women to screen themselves for breast cancer through "Breast Must Be Checked Pink Filter" campaign
RevitaLash(R) Cosmetics Launches Global and Local Impact Initiative in the Fight Against Breast Cancer
The Mission-Driven Lash & Brow Leader Continues Its Year-Round Breast Cancer Awareness Efforts RevitaLash(R) Cosmetics is proud to announce the company's annual Pink mission to make an impact in the...European Commission Approves Menarini Group's ORSERDU(R) (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen...Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU(R) (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
Each year in Europe more than 550,000 patients are diagnosed with breast cancer...Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU(R) (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or...
Olight donated over $143,429.03 raised from its global sale to fuel Autism Awareness
—
April is known as World Autism Awareness Month. Olight, a global en...
The world's oldest living lab rat points the way to rejuvenation
"Sima", a 47 months-old female rat, is being treated with E5, a treatment intended to recreate the circulatory environment of a young mammal; the maximum recorded lifespan for this species is 45.5 months. An experiment led by Dr. Harold...Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2-...
Krungsri supports Thanyarak Foundation in screening breast cancer among disadvantaged women
—
Krungsri (Bank of Ayudhya PCL), by Mr. Poonsit Wongthawatcha...